MGMT and breast carcinoma: As MGMT over expression is the most important predictor for temozolomide resistance [42] this study confirms in a preclinical breast cancer model that MGMT inhibition could increase sensitivity to temozolomide in breast cancer suggesting a basis for reconsideration of Temozolomide use in combination with an MGMT inhibitor in patients with brain metastatic disease.